The discovery of rivaroxaban: Translating preclinical assessments into clinical practice

Frontiers in Pharmacology

Volumn 4 NOV, Issue , 2013, Pages

  Kubitza, Dagmar ^a   Perzborn, Elisabeth ^a   Berkowitz, Scott D ^b  

^a BAYER PHARMA AG   (Germany)

^b BAYER CORPORATION   (United States)

Author keywords

Anticoagulation; Factor Xa inhibition; Pharmacodynamics; Prothrombin time; Rivaroxaban; Thrombin generation

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450 3A4; ENOXAPARIN; ERYTHROMYCIN; FLUCONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; NAPROXEN; PLACEBO; RITONAVIR; RIVAROXABAN; WARFARIN;

AGE; ANTITHROMBOTIC ACTIVITY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING TEST; BODY WEIGHT; CLINICAL PRACTICE; CONCENTRATION RESPONSE; DEEP VEIN THROMBOSIS; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; HEMOSTASIS; HIGH THROUGHPUT SCREENING; HUMAN; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTHROMBIN TIME; REVIEW; SINGLE DRUG DOSE; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOSIS PREVENTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84889648578     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00145     Document Type: Review

References (55)

1. Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., and Palareti, G. (2012). Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141, e44S-e88S. doi: 10.1378/chest.11-2292
2. Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., et al. (2007). Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116, 180-187. doi: 10.1161/CIRCULATIONAHA.106.668020
3. Bayer Pharma AG. (2013). Xarelto® (rivaroxaban) Summary of Product Characteristics. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
4. Biemond, B. J., Perzborn, E., Friederich, P. W., Levi, M., Buetehorn, U., and Büller, H. R. (2007). Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor. Thromb. Haemost. 97, 471-477. doi: 10.1160/TH06-11-0620
5. Brummel-Ziedins, K. E., Orfeo, T., Gissel, M., Mann, K. G., and Rosendaal, F. R. (2012). Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation. PLoS ONE 7:e29178. doi: 10.1371/journal.pone.0029178
6. Davidson, B. L., Verheijen, S., Lensing, A. W. A., and Gebel, M. (2013). Risk of bleeding in patients with acute venous thromboembolism treated with rivaroxaban or enoxaparin/VKA and concomitant ASA therapy or NSAIDs: subanalysis from EINSTEIN DVT and PE studies. J. Thromb. Haemost. 11(Suppl. s2), Abstract AS 17.1. doi: 10.1111/jth.12284
7. Depasse, F., Busson, J., Mnich, J., Le Flem, L., Gerotziafas, G. T., and Samama, M. M. (2005). Effect of BAY 59-7939-a novel, oral, direct factor Xa inhibitor-on clot-bound factor Xa activity in vitro. J. Thromb. Haemost. 3(Suppl. s1), Abstract P1104. doi: 10.1111/j.1538-7836.2005.0300c.x
8. Dunwiddie, C., Thornberry, N. A., Bull, H. G., Sardana, M., Friedman, P. A., Jacobs, J. W., et al. (1989). Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J. Biol. Chem. 264, 16694-16699.
9. Eriksson, B. I., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., et al. (2006). A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114, 2374-2381. doi: 10.1161/CIRCULATIONAHA.106.642074
10. Eriksson, B. I., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., et al. (2007a). Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb. Res. 120, 685-693. doi: 10.1016/j.thromres.2006.12.025
11. Eriksson, B. I., Misselwitz, F., and Mueck, W. (2007b). Pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban: a comparison of once-and twice-daily dosing in patients undergoing total hip replacement (THR). J. Thromb. Haemost. 5(Suppl. 1), Abstract P-M-659.
12. Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., et al. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765-2775. doi: 10.1056/NEJMoa0800374
13. Eriksson, B. I., Rosencher, N., Friedman, R. J., Homering, M., and Dahl, O. E. (2012). Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb. Res. 130, 147-151. doi: 10.1016/j.thromres.2011.12.005
14. Garcia, D. A., Baglin, T. P., Weitz, J. I., and Samama, M. M. (2012). Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141, e24S-e43S. doi: 10.1378/chest.11-2291
15. Gerotziafas, G. T., Elalamy, I., Depasse, F., Perzborn, E., and Samama, M. M. (2007). In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J. Thromb. Haemost. 5, 886-888. doi: 10.1111/j.1538-7836.2007.02429.x
16. Gnoth, M. J., Buetehorn, U., Muenster, U., Schwarz, T., and Sandmann, S. (2011). In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J. Pharmacol. Exp. Ther. 338, 372-380. doi: 10.1124/jpet.111.180240
17. Graff, J., von Hentig, N., Misselwitz, F., Kubitza, D., Becka, M., Breddin, H. K., et al. (2007). Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J. Clin. Pharmacol. 47, 1398-1407. doi: 10.1177/0091270007302952
18. Graff, J., von Hentig, N., Misselwitz, F., Kubitza, D., Becka, M., Breddin, H. K., et al. (2008). Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity: errata. J. Clin. Pharmacol. 48, 1368. doi: 10.1177/0091270008326304
19. Ieko, M., Tarumi, T., Takeda, M., Naito, S., Nakabayashi, T., and Koike, T. (2004). Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J. Thromb. Haemost. 2, 612-618. doi: 10.1111/j.1538-7933.2004.00649.x
20. Kakkar, A. K., Brenner, B., Dahl, O. E., Eriksson, B. I., Mouret, P., Muntz, J., et al. (2008). Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372, 31-39. doi: 10.1016/S0140-6736(08)60880-6
21. Koller, F. (1960). History of factor X. Thromb. Diath. Haemorrh. 4(Suppl.), 58-65.
22. Kubitza, D., Becka, M., Mueck, W., Halabi, A., Maatouk, H., Klause, N., et al. (2010). Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br. J. Clin. Pharmacol. 70, 703-712. doi: 10.1111/j.1365-2125.2010.03753.x
23. Kubitza, D., Becka, M., Mueck, W., and Schwers, S. (2012a). Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals 5, 279-296. doi: 10.3390/ph5030279
24. Kubitza, D., Becka, M., Roth, A., and Mueck, W. (2012b). Absence of clinically relevant interactions between rivaroxaban-an oral, direct factor Xa inhibitor-and digoxin or atorvastatin in healthy subjects. J. Int. Med. Res. 40, 1688-1707. doi: 10.1177/030006051204000508
25. Kubitza, D., Becka, M., Mueck, W., and Zuehlsdorf, M. (2006). Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J. Clin. Pharmacol. 46, 981-990. doi: 10.1177/0091270006292127
26. Kubitza, D., Becka, M., Mueck, W., and Zuehlsdorf, M. (2007a). Rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br. J. Clin. Pharmacol. 63, 469-476. doi: 10.1111/j.1365-2125.2006.02776.x
27. Kubitza, D., Becka, M., Zuehlsdorf, M., and Mueck, W. (2007b). Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol. 47, 218-226. doi: 10.1177/0091270006296058
28. Kubitza, D., Becka, M., Roth, A., and Mueck, W. (2008). Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr. Med. Res. Opin. 24, 2757-2765. doi: 10.1185/03007990802361499
29. Kubitza, D., Becka, M., Roth, A., and Mueck, W. (2013). The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor. J. Clin. Pharmacol. 53, 249-255. doi: 10.1002/jcph.5
30. Kubitza, D., Becka, M., Voith, B., Zuehlsdorf, M., and Wensing, G. (2005a). Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78, 412-421. doi: 10.1016/j.clpt.2005.06.011
31. Kubitza, D., Becka, M., Wensing, G., Voith, B., and Zuehlsdorf, M. (2005b). Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61, 873-880. doi: 10.1007/s00228-005-0043-5
32. Kubitza, D., and Haas, S. (2006). Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin. Investig. Drugs 15, 843-855. doi: 10.1517/13543784.15.8.843
33. Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., et al. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776-2786. doi: 10.1056/NEJMoa076016
34. Leadley, R. J. Jr. (2001). Coagulation factor Xa inhibition: biological background and rationale. Curr. Top. Med. Chem. 1, 151-159. doi: 10.2174/1568026013395380
35. Mann, K. G., Brummel, K., and Butenas, S. (2003). What is all that thrombin for? J. Thromb. Haemost. 1, 1504-1514. doi: 10.1046/j.1538-7836.2003.00298.x
36. McRae, S. J., and Ginsberg, J. S. (2004). Initial treatment of venous thromboembolism. Circulation 110, I3-I9. doi: 10.1161/01.CIR.0000140904.52752.0c
37. Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J. P., Bhatt, D. L., Bode, C., et al. (2012). Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9-19. doi: 10.1056/NEJMoa1112277
38. Mueck, W., Agnelli, G., and Büller, H. (2007). Rivaroxaban has predictable pharmacokinetics (PK) and pharmacodynamics (PD) when given once or twice daily for the treatment of acute, proximal deep vein thrombosis (DVT). Blood (ASH Annual Meeting Abstracts) 110, Abstract 1880.
39. Mueck, W., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., et al. (2008). Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb. Haemost. 100, 453-461. doi: 10.1160/TH07-12-0714
40. Mueck, W., Kubitza, D., and Becka, M. (2013). Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br. J. Clin. Pharmacol. 76, 455-466. doi: 10.1111/bcp.12075
41. Mueck, W., Lensing, A. W., Agnelli, G., Decousus, H., Prandoni, P., and Misselwitz, F. (2011). Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin. Pharmacokinet. 50, 675-686. doi: 10.2165/11595320-000000000-00000
42. Nicolini, F. A., Lee, P., Malycky, J. L., Lefkovits, J., Kottke-Marchant, K., Plow, E. F., et al. (1996). Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul. Fibrinolysis 7, 39-48. doi: 10.1097/00001721-199601000-00005
43. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891. doi: 10.1056/NEJMoa1009638
44. Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., and Misselwitz, F. (2011). The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug Discov. 10, 61-75. doi: 10.1038/nrd3185
45. Perzborn, E., Strassburger, J., Wilmen, A., Pohlmann, J., Roehrig, S., Schlemmer, K. H., et al. (2005). In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J. Thromb. Haemost. 3, 514-521. doi: 10.1111/j.1538-7836.2005.01166.x
46. Rand, M. D., Lock, J. B., van't Veer, C., Gaffney, D. P., and Mann, K. G. (1996). Blood clotting in minimally altered whole blood. Blood 88, 3432-3445.
47. Stampfuss, J., Kubitza, D., Becka, M., and Mueck, W. (2013). The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int. J. Clin. Pharmacol. Ther. 51, 549-561. doi: 10.5414/CP201812
48. The EINSTEIN Investigators. (2010). Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499-2510. doi: 10.1056/NEJMoa1007903
49. The EINSTEIN-PE Investigators. (2012). Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366, 1287-1297. doi: 10.1056/NEJMoa1113572
50. Turpie, A. G. G., Bauer, K. A., Eriksson, B. I., Lassen, M. R., and Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. (2002). Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med. 162, 1833-1840. doi: 10.1001/archinte.162.16.1833
51. Turpie, A. G. G., Eriksson, B. I., Mueck, W., Bauer, K. A., Borris, L. C., Dahl, O. E., et al. (2006). Pharmacokinetic and pharmacodynamic analyses of rivaroxaban in patients undergoing orthopaedic surgery. Pathophysiol. Haemost. Thromb. 35, Abstract 1182. doi: 10.1159/000093567
52. Turpie, A. G. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., et al. (2009). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373, 1673-1680. doi: 10.1016/S0140-6736(09)60734-0
53. Weinz, C., Buetehorn, U., Daehler, H. P., Kohlsdorfer, C., Pleiss, U., Sandmann, S., et al. (2005). Pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-in rats and dogs. Xenobiotica 35, 891-910. doi: 10.1080/00498250500250493
54. Weinz, C., Schwarz, T., Kubitza, D., Mueck, W., and Lang, D. (2009). Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs and humans. Drug Metab. Dispos. 37, 1056-1064. doi: 10.1124/dmd.108.025569
55. Willmann, S., Becker, C., Burghaus, R., Coboeken, K., Edginton, A., Lippert, J., et al. (2013). Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin. Pharmacokinet. doi: 10.1007/s40262-40013-0090-5. [Epub ahead of print].